Cardiology pp 209-216 | Cite as

General and Local Factors in Arterial Thrombosis: Platelets, Prostaglandins and Postulates

  • J. P. Caen
  • J. Maclouf

Abstract

The discovery by Moneada et al., (1976) that vessel fragments could convert prostaglandin endoperoxide G2 in an unstable metabolite with a potent antiaggregating as well as vasodilating property appeared to be a major step in the understanding of arterial thrombosis. The fact that this substance was mainly produced in the endothelial cells of the vessel wall (Moneada et al., 1977) seemed to be an additional explanation to the non thrombogenicity of the endothelium. These discoveries were followed by the emergence of the concept of antagonistic substances, namely platelet thromboxane (TX) A2 and vascular prostaglandin (PG) I2 playing a key role in the thrombocyte-vessel wall interactions. According to this concept, a balance might exist between TXA2 and PGI2 for the homeostatic regulation of platelet-vessel wall interactions. This very tempting hypothesis has stimulated a tremendous effort in the cardiovascular field, aimed at the verification of this theory as a likely explanation of most thrombotic disorders. However, at the present time, it appears that the TXA2 “ PGI2 axis may only be one part of the mediators that play a role in vascular disorders. Plasma factors, membrane components, blood cells other than platelets... may be involved in those processes.

Keywords

Platelet Adhesion Arterial Thrombosis Eicosatetraenoic Acid Bovine Endothelial Cell Platelet Thromboxane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baumgartner, H. R., and Muggli, R., 1976, Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. Platelets in Biology and Pathology, J. L. Gordon, ed., pp23. Elsevier/North Holland Biomedical Press, Amsterdam.Google Scholar
  2. Berlin, E., Matusik, E. J. Jr., and Young C. Jr., 1980, Effect of dietary fat on the fluidity of platelet membranes, Lipids 15:604.PubMedCrossRefGoogle Scholar
  3. Dyerberg, J., Bang, H. O., Stoffersen, E., Moneada, S., and Vane, J. R. , 1978, Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis, Lancet 2:117.PubMedCrossRefGoogle Scholar
  4. Fuster, V., Bowie, E. J. W., Lewis, J. C., 1978, Resistance to arteriosclerosis in pigs with von Willebrand’s disease: Spontaneous and high cholesterol diet-induced arteriosclerosis, J.Clin.Invest., 61:722.PubMedCrossRefGoogle Scholar
  5. Gryglewski, R. J., Korbut, R., and Ocetkiewicz, A. C., 1978, Generation of prostacyclin by lungs in vivo and its release into arterial circulation, Nature 273:765.PubMedCrossRefGoogle Scholar
  6. Higgs, E. A., Moneada, S., Vane, J. R., Caen, J. P., Michel, H., and Tobelem, G., 1978, Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium, Prostaglandins 16:17.PubMedGoogle Scholar
  7. Hornstra, G., Christ-Hazelhof, E., Haddeman, E., Tenhoor, F., and Nugteren, D. H., 1981, Fish oil feeding lowers thromboxane and prostacyclin production by rat platelets and aorta and does not result in the formation of prostaglandin I3, Prostaglandins 21:727.PubMedGoogle Scholar
  8. Ingerman-Wojenski, C., Silver, M. J. Smith, J. B., and Macarak, E., 1981, Bovine endothelial cells in culture produce thromboxane as well as prostacylin, J.Clin.Invest., 67:1292.PubMedCrossRefGoogle Scholar
  9. Karniguian, A., Legrand, Y. J., and Caen, J. P., 1982, Prostaglandins: specific inhibition of platelet adhesion to collagen and relationship with cAMP level, Prostaglandins (in press).Google Scholar
  10. Kovacs, I. B., and Caen, J. P., 1979, Increased interaction of vascular endothelium and leucocytes after administration of antiplatelet serum: role in the developing vascular defect, J.Clin.Pathol., 32:445.PubMedCrossRefGoogle Scholar
  11. Legrand, Y. J., Fauvel, F., Kartalis, G., Wautier, J. L., and Caen, J. P., 1979, Specific and quantitative method for estimation of platelet adhesion to fibrillar collagen, J.Lab.Clin.Med., 94:438.PubMedGoogle Scholar
  12. Legrand, Y. J., Karniguian, A., Le Francier, P., Fauvel, F., and Caen, J. P., 1980, Evidence that a collagen-derived nona-peptide is a specific inhibitor of platelet-collagen interaction, Biochem.Biophys. Res.Commun., 96:1579.PubMedCrossRefGoogle Scholar
  13. Levy-Toledano, S., Maclouf, J. Bryon, P., Savariau, E., Hardisty, R. M., and Caen, J. P., 1982, Human platelet activation in the absence of aggregation: a Ca2+ dependent phenomenon independent of thromboxane formation. Blood (in press).Google Scholar
  14. Maclouf, J., Fruteau De Laclos, B., and Borgeat, P., 1982, Effects of 12-hydroxy-and 12-hydroperoxy-5,8,10,14-eicosatetraenoic acids on the synthesis of 5-hydroxy-6,8,11,14-eicosatetraenoic acid and leukotriene B4 in human blood leukocytes. 3rd International conference on prostaglandins, Florence 18–21 May.Google Scholar
  15. Moake, J. L., Tang, S. S., Olson, J. D., Troll, J. H. Cimo, P. L., and Davies, P. J. A., 1981, Platelets, Von Willebrand factor, and prostaglandin I2, Am.J.Physiol., 241:H54.PubMedGoogle Scholar
  16. Moneada, S., Gryglewski, R., Bunting, S., and Vane, J. R., 1976, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature 263:663.CrossRefGoogle Scholar
  17. Moneada, S., Herman, A. G., Higgs, E. A., and Vane, J. R., 1977, Differential formation of prostacyclin (PGX or PGI2), by layers of the arterial wall. An explanation for the antithrombotic properties of vascular endothelium, Thrombos.Res., 11:323.CrossRefGoogle Scholar
  18. Moneada, S., Korbut, R., Bunting, S., and Vane, J. R., 1978, Prostacyclin is a circulating hormone, Nature 273:767.CrossRefGoogle Scholar
  19. Ross, R., and Vogel, A., 1978, The platelet-derived growth factor. Cell 14:203.PubMedCrossRefGoogle Scholar
  20. Roth, G. J., and Majerus, P. W., 1975, The mechanism of the effect of aspirin on human platelets, J.Clin.Invest., 56:624.PubMedCrossRefGoogle Scholar
  21. Salzman, P. M., Salmon, J. A., and Moneada, S., 1980, Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary artery, J.Pharmacol.Exp.Ther., 215:240.PubMedGoogle Scholar
  22. Samuelsson, B., Borgeat, P., Hammarström, S., and Murphy, R. C., 1979, Introduction of a nomenclature: Leukotrienes, Prostaglandins 17:785.PubMedGoogle Scholar
  23. Siess, W., and Dray, F., 1982, Very low levels of 6-keto-prosta-glandin F1 a in human plasma, J.Lab.Clin.Med., 99:388.PubMedGoogle Scholar
  24. Sweetnam, P. M., and Elwood, P. C., 1982, “Aspirin and secondary mortality after myocardial infarction.” The second MRC epidemiology unit trial in Cardiovascular Pharmacology of the Prostaglandins. Herman, A. G., Vanhoutte, P. M., Denolin, H., and Goossens, A., Raven Press, New York, pp383.Google Scholar
  25. Wautier, J. L., Paton, R. C., Wautier, M. P., Pintigny, Ü;., Abadie, E., Passa, P., and Caen, J. P., 1981, Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications, ft.Engl.J.Med., 305:237.CrossRefGoogle Scholar
  26. Weksler, B. B., Marcus, A. J., and Jaffe, E. A., 1977, Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells, Proc.Natl.Acad.Sci.USA., 74:3922.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • J. P. Caen
    • 1
  • J. Maclouf
    • 1
  1. 1.U. 150 INSERM, LA 334 CNRSHôpital LariboisièreParis Cedex 10France

Personalised recommendations